Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14539606 | 0.94 | ALDH1A1 (0.49) | SLC6A3ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL5658248 | 0.94 | ALDH1A1 (0.49) | SLC6A3ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL29013549 | 0.85 | SLC6A3 (0.42) | SLC6A3SLC6A2SLC6A4ACHE | |
| SCHEMBL1820474 | 0.83 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4ACHE | |
| SCHEMBL5656216 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL31384688 | 0.80 | SLC6A3 (0.45) | SLC6A3SLC6A2SLC6A4ACHE | |
| SCHEMBL5657293 | 0.79 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL8636289 | 0.79 | SLC6A3 (0.53) | SLC6A3SLC6A2SLC6A4ACHE | |
| SCHEMBL5656195 | 0.78 | ATR (0.39) | SLC6A3ALDH1A1SLC6A2SLC6A4ACHE | |
| SCHEMBL5657803 | 0.78 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214813-B2 | Preparation of chiral cyclic amino acids and derivatives | THE PENN STATE RESEARCH FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214813-B2 | Preparation of chiral cyclic amino acids and derivatives | THE PENN STATE RESEARCH FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-20040242889-A1 | Preparation of chiral cyclic amino acids and derivatives | THE PENN STATE RESEARCH FOUNDATION | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242889-A1 | Preparation of chiral cyclic amino acids and derivatives | AADAT, PAM, BCAT2 | SLC6A3 2914/4885ALDH1A1 2383/4885KDM4E 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.